SG Americas Securities LLC boosted its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 72.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 13,293 ...

Analysts at Wedbush lowered their Q1 2025 EPS estimates for Xenon Pharmaceuticals in a note issued to investors on Thursday, January 23rd. Wedbush analyst L. Chico now anticipates that the ...

Analyst firms have expressed optimism about Xenon's trajectory. H.C. Wainwright has maintained a Buy rating and a price target of $53.00 for Xenon, due to the potential of Azetukalner. RBC Capital ...

Ian Mortimer, President and CEO of Xenon Pharmaceuticals Inc. (NASDAQ:XENE), recently reported a series of transactions involving the company's common shares. According to a filing with the Securities ...

Analyst Christian Glennie of Stifel Nicolaus maintained a Buy rating on Polarean Imaging (PLLWF – Research Report), with a price target of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hey! This is Meghana. Hope ...

adding to the already significant number on the "climbing Mount Everest" price tag. For another, xenon has been on the list of World Anti-Doping Agency since 2014 after reports of it being used at ...

Cinemas across the USA, UK and Europe are to get an image quality boost with the announcement by Regal Cineworld that it is bringing Barco laser projection to 4000 screens.

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener The latest ...

Xenon Pharmaceuticals' Azetukalner has good Phase ... so that could definitely help justify its premium price tag today. However, I also estimate its recent quarter burned through $51.7 million.